BRPI0800957A2 - vetores biológicos compreendendo o gene max, método de produção dos mesmos, método de expressão do gene max nas células e método de terapia gênica citoprotetora - Google Patents

vetores biológicos compreendendo o gene max, método de produção dos mesmos, método de expressão do gene max nas células e método de terapia gênica citoprotetora

Info

Publication number
BRPI0800957A2
BRPI0800957A2 BRPI0800957-0A BRPI0800957A BRPI0800957A2 BR PI0800957 A2 BRPI0800957 A2 BR PI0800957A2 BR PI0800957 A BRPI0800957 A BR PI0800957A BR PI0800957 A2 BRPI0800957 A2 BR PI0800957A2
Authority
BR
Brazil
Prior art keywords
gene
max
cells
max gene
cytoprotective
Prior art date
Application number
BRPI0800957-0A
Other languages
English (en)
Inventor
Rafael Linden
Hilda Petrs Silva
Original Assignee
Univ Rio De Janeiro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rio De Janeiro filed Critical Univ Rio De Janeiro
Priority to BRPI0800957-0A priority Critical patent/BRPI0800957A2/pt
Priority to US12/936,352 priority patent/US20110086090A1/en
Priority to JP2011502198A priority patent/JP2011516047A/ja
Priority to PCT/BR2009/000093 priority patent/WO2009121157A1/en
Publication of BRPI0800957A2 publication Critical patent/BRPI0800957A2/pt
Priority to US13/683,632 priority patent/US20130184332A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

VETORES BIOLóGICOS COMPREENDENDO O GENE MAX, MéTODO DE PRODUçãO DOS MESMOS, MéTODO DE EXPRESSãO DO GENE MAX NAS CéLULAS E MéTODO DE TERAPIA GêNICA CITOPROTETORA. A presente invenção está relacionada a construções de vetores de clonagem contendo o gene max. Especialmente, a presente invenção trata da introdução dos vetores de clonagem contendo o gene max nas células utilizando vetores de transporte. Adicionalmente, a presença de vetores de clonagem contendo o gene max nas células permite a expressão diferencial do gene max nas mesmas células. Adicionalmente, a presente invenção refere-se a um método de terapia gênica no qual a expressão diferencial do gene max possui atividade citoprotetora, especialmente neuroprotetora, podendo ser aplicada a terapéutica médica e veterinária para condições de neurodegeneração.
BRPI0800957-0A 2008-04-04 2008-04-04 vetores biológicos compreendendo o gene max, método de produção dos mesmos, método de expressão do gene max nas células e método de terapia gênica citoprotetora BRPI0800957A2 (pt)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0800957-0A BRPI0800957A2 (pt) 2008-04-04 2008-04-04 vetores biológicos compreendendo o gene max, método de produção dos mesmos, método de expressão do gene max nas células e método de terapia gênica citoprotetora
US12/936,352 US20110086090A1 (en) 2008-04-04 2009-04-03 Vectors Containing the Max Gene
JP2011502198A JP2011516047A (ja) 2008-04-04 2009-04-03 Ｍａｘ遺伝子含有ベクター
PCT/BR2009/000093 WO2009121157A1 (en) 2008-04-04 2009-04-03 Vectors containing the max gene
US13/683,632 US20130184332A1 (en) 2008-04-04 2012-11-21 Vectors Containing the Max Gene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0800957-0A BRPI0800957A2 (pt) 2008-04-04 2008-04-04 vetores biológicos compreendendo o gene max, método de produção dos mesmos, método de expressão do gene max nas células e método de terapia gênica citoprotetora

Publications (1)

Publication Number Publication Date
BRPI0800957A2 true BRPI0800957A2 (pt) 2009-11-17

Family

ID=41134762

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0800957-0A BRPI0800957A2 (pt) 2008-04-04 2008-04-04 vetores biológicos compreendendo o gene max, método de produção dos mesmos, método de expressão do gene max nas células e método de terapia gênica citoprotetora

Country Status (4)

Country Link
US (2) US20110086090A1 (pt)
JP (1) JP2011516047A (pt)
BR (1) BRPI0800957A2 (pt)
WO (1) WO2009121157A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158757A1 (en) * 2011-05-16 2012-11-22 The Trustees Of The University Of Pennsylvania Proviral plasmids for production of recombinant adeno-associated virus

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302519A (en) * 1991-09-09 1994-04-12 Fred Hutchinson Cancer Research Center Method of producing a Mad polypeptide
US5512473A (en) * 1993-01-29 1996-04-30 Brent; Roger Max-interacting proteins and related molecules and methods
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
US5811298A (en) * 1996-02-29 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Rep-max protein having anti-oncogenic activity and uses thereof
WO1998009524A1 (en) * 1996-09-06 1998-03-12 Chiron Corporation Methods and compositions for liver specific delivery of therapeutic molecules using recombinant aav vectors
US6696423B1 (en) * 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
AU9319198A (en) * 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
US6683058B1 (en) * 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6521255B2 (en) * 2000-01-13 2003-02-18 Osmotica Corp. Osmotic device containing ranitidine and a prokinetic agent
US6998118B2 (en) * 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
EP1656542A4 (en) * 2003-07-29 2008-09-03 Bristol Myers Squibb Co BIOMARKER OF MODULATION CYCLIN-DEPENDENT KINASE
US20050287565A1 (en) * 2004-05-12 2005-12-29 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production

Also Published As

Publication number Publication date
US20110086090A1 (en) 2011-04-14
JP2011516047A (ja) 2011-05-26
WO2009121157A1 (en) 2009-10-08
US20130184332A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
AU2018253578A1 (en) RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
WO2013158309A3 (en) Non-disruptive gene targeting
UA109418C2 (uk) Конструйований білок з цинковими пальцями, направлений на гени рослин, залучені до біосинтезу жирних кислот
MX2015013118A (es) Composiciones y métodos para la producción y administración de ácido ribonucleico.
WO2010141801A3 (en) Reprogramming t cells and hematophietic cells
Cao et al. Contribution of microRNA-203 to the isoflurane preconditioning-induced neuroprotection
BR112013024220B8 (pt) Métodos de introdução de um ácido nucleico de interesse em uma célula vegetal com parede celular, de expressão estável de um gene e de transferência de um gene para uma célula vegetal
PH12018500633A1 (en) Plant regulatory elements and uses thereof
WO2010111490A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
BR112013004691A2 (pt) construto de dna de ativação gênica marcada de milho, população marcada de plantas de milho, método para geração da mesma e método para gerar uma planta de milho marcada
EA201100847A1 (ru) Опосредованное рнк-интерференцией ингибирование экспрессии генов эпителиального натриевого канала (enac) c использованием малой интерферирующей нуклеиновой кислоты (минк)
AU2012358181A8 (en) Compositions and methods for the delivery of biologically active RNAs
Duan et al. Bioengineered non-coding RNA agent (BERA) in action
ATE550024T1 (de) Gezielte oligonucleotid-zusammensetzungen zur modifizierung der genexpression
Takahashi et al. A naked RNA heptamer targeting the human Bcl-2 mRNA induces apoptosis of HL60 leukemia cells
EA201171175A1 (ru) Опосредованное phk-интерференцией ингибирование экспрессии гена межклеточной адгезионной молекулы 1 (icam-1) с использованием короткой интерферирующей нуклеиновой кислоты (sihk)
WO2011054939A3 (en) Compositions and methods for inhibiting expression of kif10 genes
BRPI0800957A2 (pt) vetores biológicos compreendendo o gene max, método de produção dos mesmos, método de expressão do gene max nas células e método de terapia gênica citoprotetora
BR112015004965A2 (pt) silenciamento de gene transcricional de endogenes em plantas
WO2012021383A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF MITOGEN-ACTIVATED PROTEIN KINASE 1 (MAPK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111468A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
MX2011007776A (es) Compsiciones y metodos para inhibir la expresion de genes ptp1b.
IN2014KN02312A (pt)
EP3434772A3 (en) Compositions and methods for inhibiting expression of rrm2 genes
WO2011150921A3 (de) Zellspezifisch aktivierbare biologisch wirksame moleküle auf grundlage von sirna, verfahren zu deren aktivierung sowie applikationskit zur verabreichung

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: REFERENTE A RPI 2028 DE 17/11/2009, QUANTO AO ITEM (72).

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2343 DE 01/12/2015.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL